Phase II study combining gefitinib with etoposide in patients with hormone-refractory metastatic prostate cancer (mHRPC) after docetaxel-based therapy

Autor:	F. R. Loberiza, P. M. Townley, J. E. Elkahwaji, Ralph J. Hauke, G. K. Bascom, M. Lin, S. Batra
Rok vydání:	2010
Předmět:	Oncology Cancer Research Chemotherapy medicine.medical_specialty business.industry medicine.medical_treatment Phases of clinical research medicine.disease Prostate cancer Gefitinib Growth factor receptor Docetaxel Internal medicine medicine In patient business Etoposide medicine.drug
Zdroj:	Journal of Clinical Oncology. 28:e15071-e15071
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2010.28.15_suppl.e15071
Popis:	e15071 Background: Second-line chemotherapy after docetaxel-based regimens for mHRPC remains undefined. Epithelial growth factor receptor (EGFR) expression is increased in prostate cancer. Clinical...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f0813e17e6bd5a4002bb11548756094f https://doi.org/10.1200/jco.2010.28.15_suppl.e15071 Zobrazit plný text záznamu